KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer

Transl Lung Cancer Res. 2023 Aug 30;12(8):1830-1833. doi: 10.21037/tlcr-23-271. Epub 2023 Jul 19.

Authors

Hao Chen¹, Kentaro Yumoto², Fumihiro Kashizaki², Harumi Koizumi², Ichiro Ikeda¹, Nobuyuki Horita³, Kenichi Takahashi², Takeshi Kaneko⁴

Affiliations

¹ Chemotherapy Center, Yokohama Minami Kyosai Hospital, Yokohama, Japan.
² Department of Respiratory, Yokohama Minami Kyosai Hospital, Yokohama, Japan.
³ Chemotherapy Center, Yokohama City University Hospital, Yokohama, Japan.
⁴ Department of Pulmonology, Yokohama City University, Yokohama, Japan.

No abstract available

Keywords: Chemotherapy; KEYNOTE-407; immune checkpoint inhibitor (ICI); non-small cell lung cancer (NSCLC).

Publication types

Editorial
Comment